Livagen Peptide (Lys-Glu-Asp-Ala) 20mg

Research

Livagen (Lys-Glu-Asp-Ala) Research

Livagen is a peptide bioregulator that has been studied for its potential therapeutic effects on chromatin modification, genomic stability, enzyme activity, and its role in various conditions.

Chromatin Modification and Genomic Stability

Livagen has been shown to influence chromatin structure by inducing deheterochromatinization, which involves the decondensation of heterochromatin. This process can activate ribosomal genes and potentially counteract aging-related chromatin changes, offering new avenues for treating aging-related diseases.^[1]

In patients with atherosclerosis, Livagen, both alone and in combination with cobalt ions, has been found to normalize genomic instability. This suggests its potential in reducing chromatin condensation and improving genomic health in atherosclerosis patients.^[2]

Effects on Cardiovascular Conditions

Livagen, particularly when combined with cobalt ions, enhances the activity of nucleolar organizer regions (NORs) and increases the frequency of acrocentric chromosome associations in lymphocytes. This indicates a decondensation effect on chromatin, which may help reactivate inactivated genes, providing a protective effect in Hypertrophic Cardiomyopathy (HCM) patients.^[3]

Enzyme Activity and Opioid System Interaction

Livagen inhibits enkephalin-degrading enzymes in human serum more effectively than some known peptidase inhibitors. However, it does not interact with mu- or delta-opioid receptors, suggesting its action is specific to enzyme inhibition rather than receptor interaction.^[4][5]

Digestive Enzyme Activity

Livagen administration affects digestive enzyme activity differently based on age. In young rats, it reduces enzyme activity, while in older rats, it increases activity, bringing it closer to levels observed in young control animals. This suggests Livagen’s potential in modulating enzyme activity to maintain digestive health across different ages.^[6]

Referenced Sources

1. (2023). EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE “OLD” CHROMATIN.. Georgian medical news, 335, 79-83.
2. Dzhokhadze, T., Buadze, T., Gaiozishvili, M., Kakauridze, N., & Lezhava, T. (2014). [Genomic instability in atherosclerosis].. Georgian medical news, 236, 82-6.
3. (2014). [Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].. Georgian medical news, 234, 134-7.
4. Kost, N., Sokolov, O., Gabaeva, M., Zolotarev, I., Malinin, V., & Khavinson, V. (2003). [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].. Izvestiia Akademii nauk. Seriia biologicheskaia, 4, 427-9.
5. Kost, N., Sokolov, O., Gabaeva, M., Zolotarev, Y., Malinin, V., & Khavinson, V. (2003). Effects of Livagen and Epitalon, New Peptide Bioregulators, on Enkephalin-Degrading Enzymes from Human Serum. Biology Bulletin of the Russian Academy of Sciences, 30, 351-353. https://doi.org/10.1023/A:1024809822681.
6. Timofeeva, N., Khavinson, V., Malinin, V., Nikitina, A., & Egorova, V. (2005). [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].. Advances in gerontology = Uspekhi gerontologii, 16, 92-6.